Jazz Pharmaceuticals FY Conference Summary Company Overview - **Company**: Jazz Pharmaceuticals (NasdaqGS:JAZZ) - **Date**: March 12, 2026 - **Key Speakers**: Philip Johnson (CFO), Jack Spinks (Head of Investor Relations) Core Industry Insights Financial Performance - **2025 Revenue**: Record revenue growth of 5%, driven by: - **Xywav**: 12% growth - **Epidiolex**: 9% growth - **Modeyso**: Strong initial uptake - **Consecutive Growth**: 21st consecutive year of revenue growth [3][4] Pipeline Developments - **Zepzelca**: Positive data in first-line maintenance small cell lung cancer in combination with atezolizumab - **Zanidatamab**: Unprecedented overall survival results extending beyond 2 years in first-line GEA [3][4] - **Acquisition**: Chimerix acquisition for dordaviprone, expected to yield over $200 million in tax savings [4] 2026 Guidance - **Revenue Forecast**: $4.25 billion - $4.5 billion, aiming for 22nd consecutive year of growth [4][5] Key Product Insights Xywav and Sleep Franchise - **Performance**: Continued growth in idiopathic hypersomnia and narcolepsy markets, with Xywav showing strong patient retention and safety benefits [15][17] - **Market Dynamics**: Anticipated competition from orexin agonists, but Xywav expected to remain complementary rather than competitive [20][23] Epidiolex and Epilepsy - **Market Position**: Strong IP runway with ANDA settlements extending to late 2030s; growth opportunities in adult patient populations [24][25] - **Patient Support**: Implementation of Nurse Navigator program to improve patient experiences and treatment adherence [25][27] Oncology Portfolio - **Modeyso**: Strong uptake with potential peak sales of $500 million in the US; ongoing evaluation of patient demographics and treatment duration [29][33] - **Zepzelca**: Anticipated to become standard of care in first-line maintenance setting, with expected revenue dynamics influenced by competitive landscape [43][44] Strategic Focus Areas Corporate Development - **Investment Strategy**: Focus on existing marketed products and pipeline, with plans to expand into new rare disease areas [10][11] - **Acquisition Strategy**: Targeting post-proof of concept investments in rare diseases, leveraging existing expertise [12] Future Growth Opportunities - **Oncology Expansion**: Plans to explore additional indications for zanidatamab and potential partnerships for HER2-targeted therapies [41][42] - **Research Development**: Transitioning to a fully integrated biopharma company with ongoing phase 1 assets in NRAS and KRAS programs [46] Additional Considerations - **Market Trends**: Ongoing interest in orexin agonists and their potential impact on existing therapies; Jazz positions itself as a complementary player in the market [19][20] - **Patient-Centric Approach**: Emphasis on improving patient outcomes and experiences across all therapeutic areas, particularly in epilepsy and oncology [25][27][43] This summary encapsulates the key points from the Jazz Pharmaceuticals FY Conference, highlighting the company's financial performance, product insights, strategic focus, and future growth opportunities.

Summary of Zymeworks Conference Call Company Overview - **Company**: Zymeworks - **Key Product**: Zanidatamab, a bispecific HER2 antibody developed using the Azymetric platform, which allows for advanced antibody engineering and computational biology capabilities [2][3] Financial Position - **Current Cash Position**: $271 million in cash, plus a recent $250 million royalty note, totaling over $500 million available for strategic investments [10] - **Future Milestones**: Expected $440 million in royalties from zanidatamab upon regulatory approvals, with additional $90 million for a third indication [10][12] Pipeline and Development Strategy - **Pipeline Focus**: Zymeworks aims to develop assets to inflection points and then partner them out for upfront payments while retaining long-term royalties [4][5] - **Zanidatamab**: Positioned as a transformative HER2-targeted agent with multiple mechanisms of action, showing promising data in first-line GEA and breast cancer trials [14][15][16] - **Upcoming Approvals**: Anticipated approval for zanidatamab in the second half of the year in the U.S., with Jazz Pharmaceuticals committed to filings outside the U.S. [17] Clinical Data Highlights - **GEA Study**: Positive results in progression-free survival (PFS) and overall survival (OS) when combined with checkpoint inhibitor tislelizumab [15][16] - **Folate Receptor Alpha ADC**: Early clinical data shows a wide therapeutic index and a response rate in the early 60s%, with a focus on safety and efficacy [26][28] New Molecules and Partnerships - **Pasritamig**: A T-cell engager licensed to Johnson & Johnson, currently in pivotal studies, showing manageable safety and promising efficacy [35][37] - **ZW191 (Folate Receptor Alpha)**: First asset from the wholly owned pipeline, designed to be a potential best-in-class ADC with a focus on safety and efficacy [26][28] - **ZW209 (Tri-specific)**: Expected to enter clinical trials in 2026, designed for targeted T-cell activation to enhance immune response [38] Strategic Goals - **Partnership Strategy**: Zymeworks is actively seeking partnerships for its assets, focusing on long-term royalties and reducing financial liabilities [32][33] - **Future Milestones**: Key upcoming milestones include filing for zanidatamab approval, advancing pasritamig into phase 3 studies, and sharing data from the folate receptor alpha ADC [54][55] Conclusion - Zymeworks is positioned for significant growth with a robust pipeline and strategic partnerships, focusing on innovative therapies in oncology while maintaining a strong financial position to support its development goals [5][54]

Jazz Pharmaceuticals FY Conference Summary Company Overview - **Company**: Jazz Pharmaceuticals (NasdaqGS:JAZZ) - **Event**: FY Conference on March 03, 2026 - **Key Speakers**: CFO Philip Johnson, Head of Oncology Clinical Development Amal Melhem-Bertrandt, Head of Investor Relations John Bluth Key Points Financial Performance - **2025 Achievements**: - Record revenue with the highest revenue quarter in Q4 - 21st consecutive year of revenue growth - Revenue growth: 12% in Xywav, 9% in Epidiolex, and strong start for Modeyso - Oxybate franchise surpassed $2 billion, Epidiolex exceeded $1 billion, and oncology franchise also above $1 billion [4][5] - **2026 Revenue Guidance**: - Expected total revenue between $4.25 billion and $4.5 billion, representing a 2.5% growth at the midpoint - Anticipation of 22nd consecutive year of revenue growth, driven by double-digit growth in epilepsy and oncology portfolio [7][8] Pipeline Developments - **Zanidatamab**: - Completed filing for sBLA for GEA, with a focus on first-line maintenance use in small cell lung cancers [10][11] - Data showed over 2 years of overall survival, indicating potential for practice-changing results [4][31] - **Epidiolex**: - ANDA settlements provide visibility to exclusivity into the late 2030s, with ongoing efforts to expand brand presence [25][26] - **Modeyso**: - Strong early launch performance, exceeding expectations, with peak sales potential estimated over $500 million in the U.S. [45][46] Corporate Development - **Acquisition of Chimerix**: - Enhanced oncology portfolio with Modeyso and significant financial assets, including a deferred tax asset reducing future cash taxes by over $200 million [5][6] - **Future Transactions**: - Plans for one or more transactions in 2026, focusing on epilepsy, oncology, and rare diseases [12][50] Market Dynamics - **Xywav and Generics**: - Agreement with Hikma allows authorized generic to remain until the end of 2029, with two generics already in the market [16][17] - Unique low sodium benefit of Xywav is expected to maintain its market share despite generics [17][18] - **Idiopathic Hypersomnia (IH)**: - Over 5,000 patients on Xywav for IH, with potential for growth as awareness increases [19][20] Strategic Focus - **CEO Transition**: - Successful transition from Bruce Cozadd to Renee Gala, with a refined strategy focusing on rare diseases [7] - **Expansion Opportunities**: - Interest in expanding zanidatamab into breast cancer and other indications, with ongoing studies showing promising results [41][44] Conclusion - Jazz Pharmaceuticals is positioned for continued growth in 2026, with a strong financial outlook, promising pipeline developments, and strategic corporate initiatives aimed at enhancing its market presence in rare diseases and oncology [13][50]

Summary of ALX Oncology FY Conference Call (March 03, 2026) Company Overview - **Company**: ALX Oncology (NasdaqGS:ALXO) - **Key Personnel**: Jason Lettmann (CEO), Dr. Barbara Klencke (Chief Medical Officer) - **Focus**: Advancing two novel oncology treatments: evorpacept (EVO) and ALX2004 [2][3] Core Programs Evorpacept (EVO) - **Type**: Novel CD47-targeting therapy - **Development**: In development since 2015, focusing on how cancer evades immune detection via CD47 [2][3] - **Clinical Focus**: - Currently targeting breast cancer, particularly post-HER2 treatment patients [4][5] - ASPEN breast study aims to enroll 80 patients, with top-line data expected in mid-2027 [4][20] - **Clinical Data**: - ASPEN-06 study showed a 65% response rate in HER2-positive patients compared to 26% in the control arm, indicating a 40% delta [10][11] - Combination studies with other therapies (e.g., Herceptin, zanidatamab) have shown promising results [6][10] - **Safety Profile**: No significant on-target toxicities reported, differentiating from conventional CD47 therapies [8][17] ALX2004 - **Type**: EGFR-targeted antibody-drug conjugate (ADC) - **Development**: Focused on minimizing skin toxicity and maximizing therapeutic window [21][22] - **Clinical Trials**: - Ongoing dose escalation studies, with safety data expected in the second half of 2026 [27] - Targeting EGFR overexpressing tumors, including lung, head and neck, colorectal, and esophageal cancers [27] - **Unique Features**: - Utilizes a proprietary linker and TOPO1 payload, aiming for improved efficacy and safety [22][23] Financials - **Recent Financing**: Closed a financing round of $150 million, funding operations through the first half of 2028 [5][30] - **Market Opportunity**: Approximately 20,000 addressable patients in the HER2-positive and CD47 overexpressing population [20] Strategic Outlook - **Execution Focus**: Emphasis on executing clinical studies and achieving pivotal readiness for both programs by the end of 2027 [28][30] - **Partnership Opportunities**: Open to collaborations, with a successful history of partnerships (e.g., with Sanofi) [32][33] - **Market Positioning**: Positioned to address significant unmet needs in oncology, particularly in breast cancer and EGFR-related tumors [28][29] Additional Insights - **Clinical Validation**: The unique mechanism of action of EVO, using a dead Fc to avoid on-target toxicity, has been validated across multiple studies [6][8] - **Response Rates**: High response rates in various cancer settings indicate the potential of both EVO and ALX2004 to change treatment paradigms [10][12][13] - **Future Data**: Upcoming data presentations at major conferences (e.g., ESMO Breast Cancer 2026) are anticipated to further validate the efficacy of these treatments [19][20]

Core Insights - Zymeworks reported regulatory approvals for zanidatamab monotherapy in Canada and the UK for second-line biliary tract cancer, with expectations for significant milestone payments from global approvals in gastroesophageal adenocarcinoma (GEA) and additional payments from partners Jazz and BeiGene [1][2] Financial Performance - Total revenue for 2025 was $106 million, an increase from $76.3 million in 2024, primarily driven by clinical and regulatory milestones [9] - Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, leading to a net loss of $81.1 million compared to $122.7 million in 2024 [10] Regulatory Developments - Jazz expects to submit a supplemental biologics license application (sBLA) to the FDA in Q1 2026, with zanidatamab holding Breakthrough Therapy designation for HER2-positive GEA [2] - An interim analysis for median overall survival for the zanidatamab plus chemotherapy regimen is expected by mid-2026 [3] Clinical Trials and Pipeline Updates - The Phase 3 HERIZON-GEA-01 trial showed median progression-free survival exceeding one year and median overall survival exceeding two years for zanidatamab in combination with chemotherapy [4] - Zymeworks is progressing with the Phase 1 study of ZW251, a glypican-3 antibody-drug conjugate, with plans to enroll about 100 patients [13][14] Collaboration and Financing - Zymeworks entered a $250 million non-recourse royalty-backed financing agreement with Royalty Pharma, emphasizing that this transaction is not a monetization of royalties [6][8] - The company retains milestone payments under the Jazz and BeiGene agreements, which are not used for repayment of the financing [8] Future Outlook - The company expects to fund operations beyond 2028 with existing cash resources, anticipated regulatory milestone payments, and proceeds from the royalty-backed note [11] - Adjusted gross operating expenses are projected to be about 20% lower in 2026 compared to 2025 [12]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $106 million, up from $76.3 million in 2024, driven by significant clinical and regulatory milestones and collaboration options [27] - Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, primarily due to a non-recurring impairment charge in 2024 [28][29] - Net loss improved to $81.1 million in 2025 compared to a net loss of $122.7 million in 2024, attributed to increased revenue and decreased operating expenses [30] Business Line Data and Key Metrics Changes - Revenue growth was partially offset by a decline in development support and drug supply-related revenue from Jazz, reflecting a transition of responsibilities under collaboration agreements [27] - The company reported regulatory approvals for zanidatamab as monotherapy in Canada and the UK for second-line biliary tract cancer, which is expected to translate into regulatory milestone payments of up to $440 million [12][13] Market Data and Key Metrics Changes - Consensus estimates for peak sales of zanidatamab have doubled, indicating potential for multi-billion dollar peak sales levels [12] - The company expects cumulative revenue contributions through royalties and milestones to scale meaningfully as use broadens across indications and geographies [14] Company Strategy and Development Direction - The company aims to leverage a validated scaling asset to secure efficient non-dilutive capital while preserving long-term upside [16] - Zymeworks plans to deploy capital dynamically across royalty asset acquisitions and share repurchase programs, maintaining flexibility based on market conditions [24] - The company intends to integrate new partnerships and collaborations into its existing wholly owned portfolio to share funding and risk [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding zanidatamab's potential to redefine treatment paradigms in first-line HER2-positive metastatic or locally advanced GEA [7] - The company anticipates continued discipline in capital allocation and expects adjusted gross operating expenses in 2026 to be approximately 20% lower than in 2025 [32] - Management highlighted the importance of maintaining a robust R&D operation while integrating partnerships and collaborations to enhance funding [89] Other Important Information - The company announced a strategic financing agreement with Royalty Pharma, providing $250 million of low-cost non-dilutive capital [16] - The company retains 70% of the royalty stream throughout the duration of the royalty-backed note, preserving cash flows for reinvestment [18] Q&A Session Summary Question: Regarding GPC3 ADC ZW251 enrollment and internal decision-making - Management indicated that enrollment for ZW251 is proceeding as planned, with a similar operational execution expected as seen in the ZW191 program [45][48] Question: Timing of royalty-backed financing and acquisition opportunities - Management clarified that the timing for the royalty note completion was influenced by the commercialization cycle of zanidatamab and the current cost of capital [54][56] Question: Expectations for AACR and internal R&D updates - Management hinted at significant updates on both multispecifics and ADC capabilities at the upcoming AACR conference [58][60] Question: Recent data on pasritamig and its emerging profile - Management expressed enthusiasm regarding pasritamig's safety and efficacy profile, noting positive feedback from physicians [69] Question: Types of assets targeted for acquisitions and cash runway considerations - Management stated that no acquisitions are included in the cash runway forecast, emphasizing a disciplined approach to capital deployment [74][76]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $106 million, up from $76.3 million in 2024, driven by significant clinical and regulatory milestones and collaboration options [25] - Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, primarily due to a non-recurring impairment charge in 2024 [26] - Net loss improved to $81.1 million in 2025 compared to a net loss of $122.7 million in 2024, attributed to increased revenue and decreased operating expenses [27] - Cash resources as of December 31, 2025, were $270.6 million, down from $324.2 million in 2024 [27] Business Line Data and Key Metrics Changes - Revenue growth was partially offset by a decline in development support and drug supply-related revenue from Jazz, reflecting a transition of responsibilities under the collaboration agreement [25] - The company reported regulatory approvals for zanidatamab as monotherapy in Canada and the UK for second-line biliary tract cancer, with potential milestone payments of up to $440 million for global approvals in GEA [10][11] Market Data and Key Metrics Changes - Consensus estimates for peak sales of zanidatamab have doubled, indicating potential for multi-billion dollar peak sales levels [10] - The company expects cumulative revenue contributions through royalties and milestones to scale meaningfully as use broadens across indications and geographies [11] Company Strategy and Development Direction - The company aims to leverage partnerships to accelerate the development of zanidatamab and broaden its therapeutic potential while sharing development risks [7][8] - A strategic financing agreement with Royalty Pharma provides $250 million of low-cost non-dilutive capital to fund future operations and acquisitions [13][14] - The company plans to integrate new partnerships and collaborations into its existing portfolio to share funding and risk [35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding zanidatamab's potential to redefine treatment paradigms in first-line HER2-positive metastatic or locally advanced GEA [5][6] - The company anticipates continued discipline in capital allocation and expects adjusted gross operating expenses in 2026 to be approximately 20% lower than in 2025 [30] - Management highlighted the importance of maintaining a robust R&D operation while integrating partnerships to enhance the portfolio [86] Other Important Information - The company is actively enrolling patients in the phase 1 study of ZW251, with expectations for approximately 100 patients through dose escalation [32] - The company has a cash runway extending beyond 2028, not accounting for potential acquisitions or new partnerships [72] Q&A Session Summary Question: Update on ZW251 enrollment and internal decision-making - Management indicated that enrollment for ZW251 is proceeding as planned, with a similar operational execution expected as seen in ZW191 [42][47] Question: Timing of royalty-backed financing and acquisition opportunities - Management clarified that the timing for the royalty note completion was influenced by the commercialization cycle of zanidatamab and the current cost of capital [51][52] Question: Expectations for AACR and internal R&D updates - Management hinted at significant updates on multispecifics and ADC capabilities at the upcoming AACR conference [55][58] Question: Insights on pasritamig and PTK7 development - Management expressed enthusiasm for pasritamig's safety and efficacy profile, while also discussing the strategic advantages of the biparatopic design for PTK7 [62][65]

Financial Data and Key Metrics Changes - In Q4 2025, product revenue reached $1.5 billion, representing a 32% year-over-year growth [24] - BRUKINSA global revenues totaled $1.1 billion in Q4, growing 38%, with full-year revenues of $3.9 billion, a 49% increase [24] - Gross margin improved to 87% from approximately 84% in the prior year, reflecting favorable product mix and cost efficiencies [26][27] - Operating expenses grew by 12% to $4.2 billion, with income from operations totaling $447 million, showcasing profitability [28] Business Line Data and Key Metrics Changes - BRUKINSA established itself as the leading BTK inhibitor globally, with U.S. sales of $845 million in Q4, driven by a volume growth of approximately 30% [24] - TEVIMBRA reported an 18% increase in revenue, reflecting continued market leadership in China [25] - In-licensed products showed a 9% year-over-year growth, contributing to solid execution across geographies [25] Market Data and Key Metrics Changes - The U.S. remains the largest market, generating $850 million with a year-over-year growth of 38% [25] - China revenue totaled $399 million, an 11% increase compared to Q4 2024, supported by market leadership of TEVIMBRA and BRUKINSA [26] - Europe contributed $174 million, with a 53% year-over-year growth, as BRUKINSA continues its launch trajectory [26] Company Strategy and Development Direction - The company aims to deepen its leadership in CLL and expand across hematological malignancies and solid tumors [37] - Plans to advance one to two cornerstone immunology assets towards registration, indicating a strategic shift towards immunology [37] - The company believes it can move faster and achieve better outcomes across other diseases, leveraging its foundational CLL franchise [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiated value proposition of BRUKINSA, emphasizing its safety profile and long-term efficacy [52] - The company anticipates continued strong demand growth in the U.S. with stable net pricing, projecting 2026 revenue between $6.2 billion and $6.4 billion [30] - Management highlighted the importance of addressing unmet medical needs with new product launches, including sonrotoclax and zanidatamab [30] Other Important Information - The company reported a non-recurring $40 million equity investment impairment in Q4, impacting net income [28] - Free cash flow was over $940 million for the full year 2025, indicating strong cash generation [29] - The company is optimistic about the potential of its new pipeline assets, including a proprietary off-the-shelf iPSC-derived gamma delta T-cell therapy [40] Q&A Session Summary Question: Potential net pricing development in the BTK inhibitor market - Management emphasized BRUKINSA's differentiated value proposition and its best-in-class status, which should mitigate pricing pressures from competitors entering the market [51][52] Question: Guidance assumptions regarding competition from AV or Jaypirca - Management noted that AV's clinical profile does not meet the standards for treatment in CLL, and they remain confident in BRUKINSA's position [56] Question: Strategy for immunology pipeline development - The company aims to identify 1 or 2 cornerstone assets in immunology over the next few years, with a focus on being first or best in class [61][63] Question: Impact of ZS becoming the fixed duration regimen of choice on BRUKINSA revenues - Management explained that the combination of sonrotoclax and zanubrutinib would open up a new market segment, potentially expanding overall market share [68][70] Question: Update on BTK degrader approval timeline - Management confirmed that there has been no change in the timing for the BTK degrader's approval, with plans to interact with the FDA midyear [76]

Financial Data and Key Metrics Changes - In Q4 2025, product revenue reached $1.5 billion, representing a 32% year-over-year growth [24] - BRUKINSA global revenues totaled $1.1 billion in Q4, growing 38%, with full-year revenues of $3.9 billion, reflecting a 49% increase [24][30] - Gross margin improved to 87% from approximately 84% in the prior year, driven by favorable product mix and cost efficiencies [26][27] - Operating expenses grew by 12% to $4.2 billion, while income from operations totaled $447 million, indicating profitability [28] Business Line Data and Key Metrics Changes - BRUKINSA established itself as the leading BTK inhibitor globally, with a significant gap widening against competitors [6] - TEVIMBRA reported an 18% increase in revenue, reflecting continued market leadership in China [25] - In the U.S., BRUKINSA sales in Q4 were $845 million, driven by volume growth of approximately 30% [24] Market Data and Key Metrics Changes - The CLL market is valued at $12 billion and is growing due to therapeutic innovations [7] - China revenue totaled $399 million, an 11% increase compared to Q4 2024, supported by market leadership of TEVIMBRA and BRUKINSA [26] - Europe contributed $174 million, with 53% year-over-year growth, as BRUKINSA continues its launch trajectory [26] Company Strategy and Development Direction - The company aims to deepen its leadership in CLL and expand into hematological malignancies and solid tumors [37] - Plans include advancing one to two cornerstone immunology assets towards registration [37] - The company is focused on developing a more efficacious fixed-duration regimen that addresses unmet needs in the market [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiated value proposition of BRUKINSA, emphasizing its safety and efficacy compared to competitors [52] - The company anticipates continued strong demand growth in the U.S. and stable net pricing, projecting 2026 revenue between $6.2 billion and $6.4 billion [30][31] - Management highlighted the importance of addressing the unmet needs in the CLL market and the potential for BRUKINSA to serve as a foundational therapy [38] Other Important Information - The company achieved significant product revenue growth, GAAP profitability, and meaningful cash flow generation in 2025 [6] - The R&D pipeline saw major advancements, with five assets achieving clinical proof of concept in 2025 [34] - The company is leveraging AI and automation to enhance clinical trial execution and data analysis [46] Q&A Session Summary Question: Can you comment on potential net pricing development in the BTK inhibitor market? - Management highlighted BRUKINSA's differentiated value proposition and its best-in-class status, indicating confidence in maintaining its market position despite competitive pressures [52] Question: What are the assumptions regarding competition from AV or Jaypirca? - Management noted that AV was studied in a limited patient population and expressed confidence in BRUKINSA's clinical profile, suggesting that AV does not meet the necessary treatment criteria [56] Question: Can you elaborate on the strategy for immunology beyond hematology and solid tumors? - Management indicated that approximately 20% of their assets are focused on immunology, with plans to identify one or two cornerstone assets in the next 2-3 years [62] Question: How will the introduction of ZS as a fixed-duration regimen affect BRUKINSA's revenues? - Management explained that the combination of sonrotoclax and zanubrutinib would open up a new market segment, allowing for growth without sacrificing existing revenues from continuous use [68]

Financial Data and Key Metrics Changes - In Q4 2025, product revenue reached $1.5 billion, representing a 32% year-over-year growth [23] - BRUKINSA global revenues totaled $1.1 billion in Q4, growing 38%, with full-year revenues of $3.9 billion, a 49% increase [23] - Gross margin improved to 87% from approximately 84% in the prior year, driven by favorable product mix and cost efficiencies [25] - Operating expenses grew by 12% to $4.2 billion, while income from operations totaled $447 million, indicating profitability [26] - Non-GAAP net income for 2025 was $918 million, translating to diluted non-GAAP earnings per ADS of $8.09 [27] Business Line Data and Key Metrics Changes - BRUKINSA established itself as the leading BTK inhibitor globally, capturing approximately half of the continuous BTK segment of the market [21] - TEVIMBRA reported an 18% increase in revenue, reflecting continued market leadership in China [24] - In the U.S., BRUKINSA sales in Q4 were $845 million, driven by volume growth of approximately 30% [23] - China revenue totaled $399 million, an 11% increase, supported by TEVIMBRA and BRUKINSA's market leadership [25] Market Data and Key Metrics Changes - The CLL market is valued at $12 billion and is growing due to therapeutic innovations [5] - The U.S. remains the largest market for BRUKINSA, generating $850 million with year-over-year growth of 38% [24] - Europe contributed $174 million, with 53% year-over-year growth, as BRUKINSA continues its launch trajectory [25] - Rest of world markets grew 74%, driven by market expansion and new launches [25] Company Strategy and Development Direction - The company aims to deepen its leadership in CLL with three foundational medicines and expand into hematological malignancies and solid tumors [35] - Plans include advancing one to two potential cornerstone immunology assets towards registration [35] - The company is focused on developing a more efficacious, time-limited regimen that addresses unmet needs in the CLL market [19] - The strategy includes leveraging the differentiated clinical data of BRUKINSA to maintain a competitive edge [48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for BRUKINSA and stable net pricing in the U.S. market [28] - The company anticipates revenue growth between $6.2 billion and $6.4 billion for 2026, driven by global expansion and new product launches [29] - Management highlighted the importance of clinical data in establishing BRUKINSA as a best-in-class product [48] Other Important Information - The company initiated three phase 3 studies for its BTK degrader and made significant progress in solid tumors [33] - The company is advancing a proprietary off-the-shelf iPSC-derived gamma delta T-cell therapy, which is designed to overcome limitations of existing therapies [38] - The global clinical development superhighway is a core competitive advantage, enabling faster and more efficient clinical trials [42] Q&A Session Summary Question: Can you comment on potential net pricing development in the BTK inhibitor market? - Management emphasized BRUKINSA's differentiated value proposition and its best-in-class status, which supports its pricing strategy despite competition [47][48] Question: What are the assumptions regarding competition from AV or Jaypirca? - Management expressed confidence in BRUKINSA's clinical profile and its positioning against competitors, noting that AV does not meet the necessary treatment standards [50][52] Question: Can you clarify the strategy for immunology beyond hematology and solid tumors? - Management indicated that about 20% of their assets are focused on immunology, with plans to identify one or two cornerstone assets in the next 2-3 years [57][59] Question: How will ZS impact continuous BRUKINSA revenues if it becomes the fixed duration regimen of choice? - Management explained that the combination of sonrotoclax and zanubrutinib would open up a new market segment, expanding overall market opportunities rather than cannibalizing existing revenues [61][63] Question: What is the status of the BTK degrader and its potential approval timeline? - Management confirmed that there has been no change in the timing for the BTK degrader's approval, with plans to interact with the FDA midyear [70][71]